Full-Time

Patient Access Liaison

Posted on 3/28/2026

Intellia Therapeutics

Intellia Therapeutics

201-500 employees

CRISPR-Cas9 genome-editing therapeutics developer

Compensation Overview

$193.5k - $236.5k/yr

+ Performance-based Annual Cash Bonus + New Hire Equity Grant + Annual Equity Awards Eligibility

Cambridge, MA, USA

Hybrid

Category
Consulting (2)
,
Requirements
  • Bachelor’s degree in life sciences, business, healthcare administration, or related field.
  • 7+ years of experience in patient access, field reimbursement, specialty pharmacy/Hub services, or market access within the biopharmaceutical or healthcare industry.
  • Experience supporting product launches in the U.S.
  • Familiarity with healthcare compliance requirements and payer policies across commercial and government channels.
  • Willingness to travel up to 60% to engage with sites, teams, and stakeholders.
Responsibilities
  • Serve as the primary field-facing expert for reimbursement, access, and logistical support for lonvo-z across assigned accounts.
  • Educate provider staff on coverage expectations, coding and billing requirements, prior authorization processes, appeals pathways, and financial assistance resources.
  • Conduct detailed site profiling to assess operational readiness, identifying potential bottlenecks in coverage, inventory, scheduling, infusion capacity, or workflow.
  • Work closely with the Hub and case managers to troubleshoot patient-specific reimbursement or access challenges.
  • Support the execution of access strategies designed by the Team Lead by identifying coverage trends, access barriers, and opportunities for proactive intervention.
  • Facilitate communication between sites of care, payers, and internal teams to resolve issues related to denials, payment delays, single case agreements, and other reimbursement complexities.
  • Provide real-time insights from the field to inform reimbursement tools, provider resources, and cross-functional planning.
  • Build strong relationships with key access-related personnel, including practice administrators, billing staff, infusion center managers, financial counselors, and reimbursement specialists.
  • Act as a trusted resource to providers by delivering clear guidance on policies, payer trends, and documentation requirements.
  • Partner with internal stakeholders (Market Access, Payer Accounts, Policy, Case Management) to ensure alignment on strategy and messaging.
  • Support site onboarding and training for new prescribers and infusion centers as they prepare to initiate therapy.
  • Gather insights on payer environments, patient affordability trends, and site operational needs—and communicate them promptly to the Team Lead.
  • Ensure all access and reimbursement activities comply with company policies, healthcare laws/regulations, and OIG guidance.
  • Maintain accurate documentation of field activities, access issues, and case resolution progress in accordance with company systems and SOPs.
  • Adhere strictly to non-promotional boundaries while providing education and support.
Desired Qualifications
  • Experience in rare disease and/or hereditary angioedema (HAE) strongly preferred.
  • Experience in field reimbursement, specialty pharmacy, or market access within biopharmaceutical or healthcare industry.
Intellia Therapeutics

Intellia Therapeutics

View

Intellia Therapeutics develops CRISPR-Cas9 genome editing therapies to treat severe genetic diseases. Its work centers on using CRISPR to edit genes and delivering the editing tools to the right cells with a modular lipid nanoparticle system, aiming to create treatments that can be given to patients and move through clinical trials toward market. The company earns revenue through R&D collaborations, licensing, and potential sales of approved therapies. Compared to others in biotech, Intellia emphasizes in vivo gene editing using a distinctive lipid nanoparticle delivery approach and active partnerships to advance candidates. Its goal is to bring safe, effective genome-editing treatments to patients while building value through collaborations and licensing.

Company Size

201-500

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2014

Your Connections

People at Intellia Therapeutics who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Phase 3 HAELO trial showed an 87% attack reduction versus placebo, driving positive regulatory momentum toward a 2H 2026 BLA[2][5].
  • FDA granted Regenerative Medicine Advanced Therapy designation, expediting review and potentially enabling a 1H 2027 U.S. launch[2][4].
  • Intellia's $605.1 million cash reserve funds operations into late 2027, reducing near-term dilution pressure before commercialization[2][9].

What critics are saying

  • FDA delay or rejection risk remains high due to only six-month efficacy data, with launch possibly delayed beyond 2027[2][5].
  • Safety overhang from infusion reactions, headaches, and a grade 2 liver enzyme elevation could trigger labeling restrictions or slower adoption[5][9].
  • Single near-term launch dependence makes operations vulnerable to lonvo-z setbacks, as the company lacks other commercial products yet[2][5].

What makes Intellia Therapeutics unique

  • Intellia pioneers the first in vivo CRISPR therapy with lonvo-z, unlike Vertex's ex vivo Casgevy[7][8].
  • Its one-time outpatient dosing permanently cures hereditary angioedema by targeting the KLKB1 gene, ending chronic treatment needs[5][6].
  • The company holds exclusive access to a comprehensive CRISPR-Cas9 IP platform while advancing ex vivo and in vivo pipelines[1][2].

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Family Planning Benefits

Fertility Treatment Support

Parenting Leave

Adoption Assistance

Childcare Support

Elder Care Support

Commuter Benefits

Meal Benefits

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-4%

2 year growth

-3%
Minaris Advanced Therapies
Apr 29th, 2026
Improving manufacturing reliability in cell and gene therapy: practical operational strategies.

Improving manufacturing reliability in cell and gene therapy: practical operational strategies. April 29, 2026 CDMO Services Cell Therapy Gene Therapy Viral Vectors Gain practical insight into how to improve manufacturing reliability, reduce cost per batch, and strengthen performance in cell and gene therapy programs. This webinar will demonstrate how structured assessment of materials, process steps, testing workflows, and operational handoffs reveals actionable opportunities to shorten timelines and reduce variability. Using real-world examples and techniques that can be applied across multiple therapy types and development stages, the session will show how early operational assessment and targeted workflow adjustments lead to measurable improvements. These include smoother transitions into GMP manufacturing, fewer late-stage process changes, and sustained success during routine production. Key takeaways * Learn how mapping the current state of a manufacturing program across materials, unit operations, testing, and handoffs reveals actionable opportunities to reduce cost, minimize variability, and improve right-first-time statistics * Understand how standardized workflows combined with expertise support smoother transitions into GMP manufacturing and reduce late-stage process changes * Review generalized case examples demonstrating reductions in cost per batch, improved manufacturing reliability, and sustained success during routine production * Gain a practical framework for evaluating your own program, identifying improvement priorities early, and working with partners to optimize processes without disrupting timelines About the speaker. Francesca Vitelli Vice President, Global Head of Process, Analytical Development and Innovation Francesca Vitelli, PhD, is a biotechnology leader with more than 20 years of experience in process and analytical development, manufacturing, and CMC strategy across cell and gene therapies. At Minaris Advanced Therapies, she leads global teams responsible for advancing innovative, platform-based manufacturing solutions for cell therapies and viral vectors, with a focus on de-risking CMC execution, enabling reliable GMP delivery, and accelerating the adoption of new technologies to improve scalability, robustness, and patient access. Previously, Dr. Vitelli served as Vice President at Intellia Therapeutics, where she led process development and manufacturing for both in vivo and ex vivo gene editing programs, expanding technical capabilities while driving operational efficiencies. Prior to Intellia, she held senior leadership roles at Lonza, where she launched large-scale viral vector manufacturing platforms and led cell therapy manufacturing for clinical and commercial-ready programs. Dr. Vitelli is recognized for her technical rigor, innovation-driven mindset, and ability to scale organizations through periods of rapid growth. She holds a PhD from the University of Siena. Related resources.

Yahoo Finance
Feb 28th, 2026
Intellia Therapeutics reports $605M cash reserves, expects runway into 2027

Intellia Therapeutics has reported its fiscal Q4 and full year 2025 financial results, with cash, cash equivalents and marketable securities of $605.1 million as of 31 December 2025, down from $861.7 million in the prior year. The company expects these funds to support operations into the second half of 2027, including through the anticipated US commercial launch of lonvo-z for hereditary angioedema. Collaboration revenue for Q4 reached $23.0 million, up from $12.9 million year-on-year, driven by $9.0 million from the termination of its licence agreement with SparingVision and increased cost reimbursements from its Regeneron collaboration. Research and development expenses fell to $88.7 million from $116.9 million in the prior year period. The clinical-stage company develops genome editing therapeutics using CRISPR/Cas9 technology.

Yahoo Finance
Feb 28th, 2026
Intellia completes phase 3 enrollment for lonvo-z, aims for mid-2026 data with $605M cash

Intellia Therapeutics has completed enrolment in its phase 3 HAELO trial for lonvo-z, expecting top-line data by mid-2026 and planning a biologics licence application submission in the second half of 2026. The company is preparing for a potential one-time hereditary angioedema treatment launch. The FDA placed Intellia's in vivo ATTR programme (nex-z) on clinical hold following liver enzyme events. The hold was lifted for the MAGNITUDE-2 polyneuropathy study with enhanced monitoring requirements, whilst the cardiomyopathy study remains on hold pending review. Intellia reported $605.1 million in cash as of 31 December 2025, sufficient to fund operations into the second half of 2027. The company posted a reduced fourth-quarter net loss of $95.8 million alongside higher collaboration revenue.

The Associated Press
Feb 26th, 2026
Intellia's lonvo-z for HAE targets mid-2026 Phase 3 data, BLA filing and 2027 US launch

Intellia Therapeutics reported fourth-quarter 2025 financial results and provided updates on its CRISPR gene-editing programmes. The company ended 2025 with approximately $605 million in cash, expected to fund operations into the second half of 2027. For lonvoguran ziclumeran (lonvo-z) treating hereditary angioedema, Intellia expects Phase 3 HAELO clinical data by mid-2026, with a biologics licence application submission in the second half of 2026 and anticipated US launch in the first half of 2027. The company completed dosing of 80 patients in September 2025. For nexiguran ziclumeran (nex-z) treating ATTR amyloidosis, Intellia is reactivating global sites for the MAGNITUDE-2 Phase 3 trial following the FDA's January 2026 clinical hold lift, with enrollment completion expected in the second half of 2026. Engagement continues regarding the clinical hold on the MAGNITUDE trial.

Yahoo Finance
Jan 20th, 2026
Intellia Therapeutics shares surge 35% in a month but trade 95% below DCF valuation

Intellia Therapeutics shares have surged 35.4% over the past month and 35.7% year-to-date, trading around $12.50. However, the stock scores just 2 out of 6 on valuation checks, suggesting the market prices it favourably on only a couple of basic tests. A discounted cash flow analysis estimates the company's intrinsic value at $233.98 per share, implying the stock is 94.7% undervalued at current levels. The model projects Intellia moving from negative free cash flow of $420 million in the latest twelve months to positive cash flow of approximately $370 million by 2030. Despite recent gains, the stock has posted weak longer-term returns, declining 65.2% over three years and 82.5% over five years.

INACTIVE